<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578279</url>
  </required_header>
  <id_info>
    <org_study_id>0702-25</org_study_id>
    <secondary_id>IRB # 0702-25</secondary_id>
    <secondary_id>Clarian Values Grant: vfr-262</secondary_id>
    <nct_id>NCT00578279</nct_id>
  </id_info>
  <brief_title>Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study</brief_title>
  <official_title>Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain preliminary safety and efficacy data after endoscopic
      ultrasound-guided celiac plexus neurolysis (EUS-CPN) in patients with locally advanced or
      unresectable pancreatic adenocarcinoma.

      Hypotheses:

        1. Increased amounts of alcohol used in EUS-CPN is safe and more efficacious in improving
           pain relief in patients with locally advanced or unresectable pancreatic adenocarcinoma.

        2. Effective pain relief obtained from EUS-CPN will be related to better quality of life
           (QOL)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection</measure>
    <time_frame>baseline up to 1 year</time_frame>
    <description>Pain will be assessed at baseline 24 hours after the procedure and weekly thereafter, until the subject reports no subjective pain relief from the procedure. Pain relief is defined as a decrease in 2 points on a 0-10 point pain rating scale. Zero is no pain and 10 is the worst pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subject randomized to 10ml of dehydrated alcohol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject randomized to 20ml of dehydrated alcohol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dehydrated alcohol</intervention_name>
    <description>subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A total of 20 consecutive subjects with locally advanced or unresectable pancreatic
             adenocarcinoma (stage II to IV) with pain (abdominal and/or back). Subjects with known
             or suspected unresectable pancreatic adenocarcinoma will be recruited for this study,
             as a diagnosis of unresectable pancreatic adenocarcinoma is often made during the
             endoscopic ultrasound (EUS) procedure.

          -  Subjects must have documented disease by computed tomography (CT), endoscopic
             retrograde cholangio-pancreatography (ERCP), or EUS.

          -  Subjects undergoing EUS for pancreatic cancer staging.

          -  Subjects undergoing pancreatic cancer surgery are eligible for study entry beginning 5
             days after the operation if they have not had an intraoperative celiac plexus
             neurolysis.

          -  No evidence of dementia or altered mental status that would prohibit the giving and
             understanding of informed consent, and no evidence of psychiatric risk that would
             preclude adequate compliance with this protocol.

        Subjects must not have a coagulopathy (platelet &lt;50,000, INR&gt;1.5, or bleeding disorder, or
        on blood thinners) Subjects with platelets below 50,000 will not be eligible to participate
        in this study due to the risk of bleeding. Patients will be asked to discontinue use of
        non-steroidals for 5 days prior to the procedure. Patients on plavix will be asked to
        discontinue use for 7 days prior to the procedure if they are clinically able to do so.
        Patients on coumadin or lovenox will also need to discontinue use prior to the procedure,
        but decisions regarding their management will be made on an individual basis as per our
        usual standards of care.

          -  Subjects must provide signed written informed consent.

          -  A baseline pain score is not required, however, subjects must be having pain that is
             requiring a stable dose of pain medication for control of pain.

        Exclusion Criteria:

          -  Subjects will be excluded if they have undergone a celiac plexus neurolysis
             (endoscopic, percutaneous, or surgical).

          -  Presence of an implanted epidural or intrathecal analgesic therapy. Subjects with
             psychiatric illness that affects their ability to assess quality of life or compliance
             with the protocol.

          -  Subjects with uncorrectable coagulopathy

          -  Subjects with an allergy to bupivacaine or alcohol.

          -  Presence of an aneurysm in the abdominal aorta, celiac trunk, or superior mesenteric
             artery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia LeBlanc, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clarian Health: Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>September 23, 2010</results_first_submitted>
  <results_first_submitted_qc>September 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2012</results_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>10 mL of Alcohol Injection</title>
          <description>subject randomized to 10ml of dehydrated alcohol</description>
        </group>
        <group group_id="P2">
          <title>20 mL of Alcohol Injection</title>
          <description>subject randomized to 20ml of dehydrated alcohol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 mL of Alcohol Injection</title>
          <description>subject randomized to 10ml of dehydrated alcohol</description>
        </group>
        <group group_id="B2">
          <title>20 mL of Alcohol Injection</title>
          <description>subject randomized to 20ml of dehydrated alcohol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="14"/>
                    <measurement group_id="B2" value="63" spread="10"/>
                    <measurement group_id="B3" value="64" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection</title>
        <description>Pain will be assessed at baseline 24 hours after the procedure and weekly thereafter, until the subject reports no subjective pain relief from the procedure. Pain relief is defined as a decrease in 2 points on a 0-10 point pain rating scale. Zero is no pain and 10 is the worst pain.</description>
        <time_frame>baseline up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10 mL of Alcohol Injection</title>
            <description>subject randomized to 10ml of dehydrated alcohol</description>
          </group>
          <group group_id="O2">
            <title>20 mL of Alcohol Injection</title>
            <description>subject randomized to 20ml of dehydrated alcohol</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection</title>
          <description>Pain will be assessed at baseline 24 hours after the procedure and weekly thereafter, until the subject reports no subjective pain relief from the procedure. Pain relief is defined as a decrease in 2 points on a 0-10 point pain rating scale. Zero is no pain and 10 is the worst pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="10.8"/>
                    <measurement group_id="O2" value="8.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>10 mL of Alcohol Injection</title>
          <description>subject randomized to 10ml of dehydrated alcohol</description>
        </group>
        <group group_id="E2">
          <title>20 mL of Alcohol Injection</title>
          <description>subject randomized to 20ml of dehydrated alcohol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julia K. LeBlanc, MD</name_or_title>
      <organization>Indiana University Medical Center</organization>
      <phone>(317) 948-8125</phone>
      <email>juleblan@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

